9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Items 801–900 of 975
Weeda, E. R., Alnewais, M. E., Zecopoulos, A., Haas, S., Rowe, S., & Burnette, B. (2022) · Diabetes Care · doi:10.2337/dc21-2105 · Cited by 1
Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus
Gorb, Y. G., Serik, S. A., Tkachenko, O. V., & Ryabukha, V. V. (2022) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs07.01.014 · Cited by 1
Anton, I. C., Mititelu-Tarțău, L., Popa, T., Poroch, M., Poroch, V., Reurean‐Pintilei, D., & Botnariu, G. E. (2022) · Healthcare · doi:10.3390/healthcare10071153 · Cited by 1
Precision Medicine Approaches for Management of Type 2 Diabetes
Chen, D., Fulcher, J., SCOTT, E. S., & Jenkins, A. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_1 · Cited by 3
Long-Term Maternal Complications
Kakotrichi, P., Mantsiou, C. D., Bekiari, E., & Τσάπας, Α. (2022) · Springer eBooks · doi:10.1007/978-3-030-89243-2_19 · Cited by 1
Shah, N., Perkovic, V., & Kotwal, S. S. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2108402 · Cited by 3
Icodec insulin - revolution in diabetes type 2 insulin therapy
Dobrzyński, M., Czarnota, J., Skubel, T., Drozd, M., Dudek, I., & Rybak, N. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.08.097 · Cited by 1
Insulinoterapia en pacientes con diabetes mellitus tipo 2. Una revisión narrativa
González-Wong, C., Fuentes-Barría, H., & Aguilera-Eguía, R. A. (2022) · Enfermería Universitaria · doi:10.22201/eneo.23958421e.2021.3.1096 · Cited by 6
Duman, T. T., Aktaş, G., Tel, B. M. A., Bilgin, S., Kahveci, G., & Kurtkulağı, Ö. (2022) · Journal of Public Health · doi:10.1007/s10389-022-01769-1 · Cited by 2
Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome
Kim, G. E., & Flynn, J. T. (2023) · Springer eBooks · doi:10.1007/978-3-031-06231-5_19 · Cited by 1
Harris, S. B., Mohammedi, K., Bertolini, M., White, J. C., Walker, V., Zhou, F. L., Anderson, J. E., & Seufert, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14973 · Cited by 1
Kodama, S., Fujihara, K., Ishiguro, H., Matsubayashi, Y., Kitazawa, M., Iwanaga, M., Yamada, T., Kato, K., Nakagawa, Y., Tanaka, S., et al. (2023) · Journal of Investigative Medicine · doi:10.1177/10815589221149188 · Cited by 1
Diabetes Management in the United States
Shah, M. K., Khan, F. N., & Ali, M. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_19 · Cited by 1
Bepo, L., Makam, A. N., & Nguyen, O. K. (2022) · Annals of Internal Medicine · doi:10.7326/l21-0707 · Cited by 1
Şimşek, Y., & Urhan, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.103112 · Cited by 2
Salem, A. M. H., Bain, S. C., & Obaid, D. R. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.05.010 · Cited by 1
Development of a patient decision aid for type 2 diabetes mellitus: a patient-centered approachPreprint
Tichler, A., Hertroijs, D. F. L., Ruwaard, D., Brouwers, M. C. G. J., & Elissen, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3395717/v1 · Cited by 1
Ramalan, M. A., Maiyaki, M. B., Gezawa, I., & Uloko, A. E. (2024) · medRxiv · doi:10.1101/2024.07.18.24310630 · Cited by 1
Navarro, G. M., de Miguel, A. C., Ortega, M. M., Juez, A. U., & García, M. C. G. (2021) · doi:10.52102/contexto_epidemiologico/art-5
Outpatient management of endocrine conditions during the COVID-19 pandemic
Ziganshina, A., & Gosmanov, A. R. (2021) · Kazan medical journal · doi:10.17816/kmj2021-206
Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy
Bando, H., Kato, Y., Kato, Y., Matsuzaki, S., Waka, S., & Ogura, K. (2021) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2021/asjbccr.6233
Ito, H., Araki, R., Matsumoto, S., Izutsu, T., Kusano, E., Kondo, J., Inoue, H., Antoku, S., Yamasaki, T., Mori, T., et al. (2021) · Diabetology International · doi:10.1007/s13340-021-00508-3
From Pharmacogenetics to Gene Expression: Implications for Precision Medicine in Diabetes
Sanchez-Pozos, K. A., Granados‐Silvestre, M. D. L. Á., & Ortiz‐López, M. G. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97375 · Cited by 2
Jung, C. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.203 · Cited by 2
Low HbA1c Level and High Mortality
Tanaka, A., & Node, K. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.03.006
Les inhibiteurs de SGLT2 sont d’abord des antidiabétiques oraux !
Halimi, S. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.04.006
Cobo, A. L., Masson, W. M., Lobo, M., Masson, G., & Molinero, G. B. (2021) · Research Square · doi:10.21203/rs.3.rs-664920/v1
Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas
Guduguntla, V., & Grant, R. W. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2487
Darian, M. A. (2021) · Clinical Research in Practice The Journal of Team Hippocrates · doi:10.22237/crp/1622160600
Current Perspectives for Oral Hypoglycemic Agents with Clinical Evidence of Larger Studies
Bando, H. (2021) · Diabetes Research - Open Journal · doi:10.17140/droj-7-e016
Satisfactory Control for Glucose Profile by Combined Agents of Xultophy with A Small Dose
Bando, H., Ogawa, H., Nagahiro, S., Nakanishi, M., & Watanabe, O. (2021) · doi:10.36502/2021/droa.6180
Williams, N. A., Brunton, S., & Scott, G. A. (2021) · Clinical Diabetes · doi:10.2337/cd21-0066 · Cited by 1
Role of Sodium-Glucose Cotransporter-2 Inhibitors in Readmissions for Congestive Heart Failure
Keryakos, J., Kranz, R., Propst, R., Rathert, J., & Semerad, K. (2021) · Journal of Young Pharmacists · doi:10.5530/jyp.2021.13.52
Veneti, S., & Τζιόμαλος, Κ. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967931
Barvian, C. K., & Cipriano, G. C. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211039707
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Reid (2021) · The Journal of Family Practice · doi:10.12788/jfp.0216
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
Mottl (2021) · The Journal of Family Practice · doi:10.12788/jfp.0225 · Cited by 3
Improving Shingles Vaccination Rates in Family Medicine
Luther (2021) · The Journal of Family Practice · doi:10.12788/jfp.0218
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient
Lillo (2021) · The Journal of Family Practice · doi:10.12788/jfp.0224
Prediction, diagnosis, prevention and treatment: genetic-led care of patients with diabetes
Tangjittipokin, W., Borrisut, N., & Rujirawan, P. (2021) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2021.1970526
Kwon, S., Ha, J. H., Kim, D. K., Kim, Y. S., Lim, C. S., Chang, H., Lee, J. P., & Park, J. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3859307
Metformin: We need to either put it in our drinking water or rethink how we study itPreprint
Powell, M. A., Clark, C. N., Alyakin, A., Vogelstein, J. T., & Hart, B. (2021) · medRxiv · doi:10.1101/2021.09.15.21263634
¿Por qué no insulinizamos cuando es necesario?
Simarro, F. L. (2021) · doi:10.52102/insulina/art-1 · Cited by 1
Cuándo y cómo iniciar la insulinización
Loiola, P. E. (2021) · doi:10.52102/insulina/art-2
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease
Brodosi, L., Marchignoli, F., Marchesini, G., & Petroni, M. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1980538
Unusual association of cirrhosis and sickle cell anemia revealed by hemolytic anemia: A case report
Jallouli, A., Michouar, M., Laghfiri, N., Ait, E. A., Oubaha, S., Samlani, Z., & Krati, K. (2021) · Archives of Clinical Gastroenterology · doi:10.17352/2455-2283.000103
Optimizing glucose control for diabetic patients undergoing percutaneous coronary intervention
Chang, H., & Kim, S. H. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.466
Long-Term Glycemic Control for Stroke Survivors
Kang, D.-W. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_20
Classifications des diabètes qui surviennent chez l’adulte : actualisation
Monnier, L., Fève, B., & Halimi, S. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.001
Haluzı́k, M., Kubíčková, M., Veselý, J., Linhart, A., Prázný, M., Škrha, J., Táborský, M., & Málek, F. (2021) · Cor et Vasa · doi:10.33678/cor.2021.108
Gargallo-Fernández, M., Menéndez, S. A., César, M. J. P., & Reyes‐García, R. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.11.028
Li, Q., Zhang, Q., Wang, R., & Hong, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01182-z
Gastroenterologische Komplikationen des Diabetes mellitus: Gastroparese
Weber, A.-L., Leitolf, H., & Wedemeyer, H. H. (2021) · Gastroenterologie up2date · doi:10.1055/a-1502-4925
Az SGLT-2-gátlók diabetológián túlmutató előnyei
Jermendy, G. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.20
Choix entre une gliptine et une gliflozine chez le patient âgé avec un diabète de type 2
Scheen, A. J. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.12.010
Diabetes and Kidney Disease: A Review of the Clinical Practice Guidelines
Aggarwal, N., Ali, S., & Navaneethan, S. D. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_2
As, A., & Kosyan, A. A. (2021) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2021-10-4-44-51
SGLT-2 INHIBITORS – AN ANTIDIABETIC WITH CARDIOPROTECTIVE EFFECTS
Guha, M. K. (2021) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/7904180
Prescrire l’activité physique : mais comment ? Les Maisons Sport-Santé, une initiative nationale
Halimi, S. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.12.004
Valencia, W. M., & Florez, H. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-76271-1_20
Hayes, M. J. (2022) · ADCES in Practice · doi:10.1177/2633559x221080161
Mehta, J. K., Dhaneria, S., Gaikwad, N., Keche, Y. N., Wasnik, P. N., & Siddiqui, M. S. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01049-4 · Cited by 1
Aslanabadi, N., Beheshtirouy, S., Mashayekhi, S., Heidari, Z., Hamedani, S., & Entezari‐Maleki, T. (2022) · Pharmaceutical Sciences · doi:10.34172/ps.2022.10
Chebaya, P., Gambhir, H. S., Banerjee, S., Azhar, A., Huang, N., Phogat, V., Smith, K., Sala, L., Adhikari, S., & Nye, K. D. (2022) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(22)01423-1
Howell, C., Schmelz, A. N., Albertson, S., Hamm, J. A., Meredith, A. H., Pence, L. M., Triboletti, J. S., & Gonzalvo, J. D. (2022) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1626
Santos, M. R., Artime, E., Duque, N., Díaz‐Cerezo, S., Spaepen, E., Carreño, Á., & Fernández, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01264-6
Diabetes Medications and Cardiovascular Disease Prevention
Rho, J.-S., Lee, Y.-A., Song, S.-W., & Kang, S. G. (2022) · Korean Journal of Family Practice · doi:10.21215/kjfp.2022.12.2.61
Yoo, J. H., & Kim, J. H. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_13
Agonisti del recettore del GLP1 e infiammazione: non solo compenso glicemico
Costanzo, G., & Frasca, F. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01064-x
Ramírez, J. E. P., Beltrán, J. S. U., & Palomeque, G. A. E. (2022) · Tesla Revista Científica · doi:10.55204/trc.v9789i8788.48
Hamann, A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00929-x
Goraya, N., & Moran, J. D. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00032022
Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome
Kim, G. E., & Flynn, J. T. (2022) · Springer eBooks · doi:10.1007/978-3-319-31420-4_19-2
Prevention and correction of alpelisib-induced hyperglycemia (view of endocrinologist)
Kovalenko, I. M. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-13-44-47
Müller‐Wieland, D., & Marx, N. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-62939-0_12-1
Semaglutide: A Strategic Weapon for Primary Care
Jain, A. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u3
Expert Insights for PCPs in Managing CKD in T2DM
Wu, Y. T. A. (2022) · The Singapore Family Physician · doi:10.33591/sfp.48.3.u5
Terauchi, Y. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.1872
Hong, Y., Chen, D., Jin, Y., Zu, M., & Zhang, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.971768 · Cited by 3
Effects of GLP-1 Receptor Agonists on Cardiovascular Events and Their Clinical Positioning
Yamane, S., & Inagaki, N. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.2458
Damayanti, A., Chicade, A., Sa’diyah, H., Petrisia, K., Elwin, L. T. R., Yericho, M., Andini, M. P., Rachman, M. R., Yuzhar, M., Pebrianti, P., et al. (2022) · Journal Pharmaceutical Care and Sciences · doi:10.33859/jpcs.v2i2.160 · Cited by 1
McCulley, L., & Hurren, K. M. (2022) · Federal Practitioner · doi:10.12788/fp.0319 · Cited by 1
Geliebter, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-15353-2_7
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Insulin deficient type 2 diabetics: Urgent need for enhanced research in Pakistan
Afzal, M. N. (2022) · Journal of Fatima Jinnah Medical University · doi:10.37018/bbvb7249
Feng, S., Cai, L., Wang, X., Yu, Q., Cai, J., Hao, W., Chen, Z., Su, X., Du, C., Zou, Q., et al. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1187
Nedogoda, S. V., Barykina, I. N., Salasyuk, A. S., Lutova, V. O., & Popova, E. A. (2022) · Diabetes Mellitus · doi:10.14341/dm12774 · Cited by 1
代, 琳. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.132386
Formel zur Abschätzung der Dosierung bei Neueinstellung auf Insulin
Hoffmann, R. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01024-5
Medications to Avoid When Treating Heart Failure
Cox, Z. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-20193-6_18
Diabetes: evolution of multifactorial vascular risk reduction
Falcetta, P., Garofolo, M., Penno, G., & Prato, S. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00007-3 · Cited by 1
Skouri, H. N., Massih, T. A., Chaaban, S., Chammas, E., Mohamad, M. A., Nasr, S., & Turquieh, F. (2023) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2023.133012
Shao, H., Tao, Y., & Tang, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1143928 · Cited by 1
Topaloğlu, Ö., & Toksöz, D. Y. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01197-1
“Glucagon like peptide 1 receptor agonists (GLP1Ra) have been increasingly used in the patients with type 2 diabetes especially if weight reduction is desired [2].”
Whitley, H. P., & Smith, W. D. (2023) · Journal of Case Reports and Images in Medicine · doi:10.5348/100073z09hw2022cs · Cited by 1
Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual
Peter, P. R., & Inzucchi, S. E. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_37
Mühlhauser, I., Buhse, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_34
Wojciechowska, J. K., Krajewski, W. R., Zatoński, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_63
Onishi, Y., Shirabe, S., Eguchi, K., Nishijima, K., Sato, T., & Seino, H. (2023) · Diabetology International · doi:10.1007/s13340-023-00638-w
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.